Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease

References

• Friedman DS, O’Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophtalmol. 2004 Apr;122(4):564–572. PubMed PMID: 15078675.
   PubMed Web of Science ®Google Scholar
• Owen CG, Jarrar Z, Wormald R, et al. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol. 2012 May;96(5):752–756. PubMed PMID: 22329913; PubMed Central PMCID: PMC3329633.
   PubMed Web of Science ®Google Scholar
• Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophtalmol. 1984;102(11):1640–1642.
   PubMed Web of Science ®Google Scholar
• Green WR, Enger C. Age-related macular degeneration histopathologic studies: the 1992 Lorenz E. Zimmerman lecture. Ophthalmology. 1993;100(10):1519–1535.
   PubMed Web of Science ®Google Scholar
• Gass JD. Pathogenesis of disciform detachment of the neuroepithelium: I. General concepts and classification. Am J Ophthalmol. 1967 Mar 1;63(3, Part 2):573/1–585/13..
   PubMedGoogle Scholar
• Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care. 2003 Sep;26(9):2653–2664. PubMed PMID: 12941734. .
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macular edema. Ophthalmology. 1995 Jan;102(1):7–16. PubMed PMID: 7831044.
   PubMed Web of Science ®Google Scholar
• Ferris FL 3rd, Patz A. Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol. 1984 May;28(Suppl):452–61. PubMed PMID: 6379946.
   PubMed Web of Science ®Google Scholar
• Ciulla TA, Harris A, Latkany P, et al. Ocular perfusion abnormalities in diabetes. Acta Ophthalmol Scand. 2002 Oct;80(5):468–477. PubMed PMID: 12390156.
   PubMedGoogle Scholar
• Ehrlich R, Harris A, Ciulla TA, et al. Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process. Acta Ophthalmol. 2010 May;88(3):279–291. PubMed PMID: 20222885.
   PubMed Web of Science ®Google Scholar
• Morello CM. Etiology and natural history of diabetic retinopathy: an overview. Am J Health Syst Pharm. 2007 Sep 1;64(17 Suppl 12):S3–7. PubMed PMID: 17720892.
   PubMed Web of Science ®Google Scholar
• Hussain RM, Ciulla TA. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy. Expert Opin Biol Ther. 2016;16(3):365–374. PubMed PMID: 26674182.
   PubMed Web of Science ®Google Scholar
• Miyamoto K, Ogura Y. Pathogenetic potential of leukocytes in diabetic retinopathy. Semin Ophthalmol. 1999 Dec;14(4):233–239. PubMed PMID: 10758224.
   PubMedGoogle Scholar
• Leung D, Cachianes G, Kuang W, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246(4935):1306–1309.
   PubMed Web of Science ®Google Scholar
• Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983 Feb 25;219(4587):983–985. PubMed PMID: 6823562.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003 Jun;9(6):669–676. PubMed PMID: 12778165.
   PubMed Web of Science ®Google Scholar
• Miller JW, Le Couter J, Strauss EC, et al. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology. 2013 Jan;120(1):106–114. PubMed PMID: 23031671.
   PubMed Web of Science ®Google Scholar
• Kim I, Moon SO, Kim SH, et al. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem. 2001 Mar 09;276(10):7614–7620. PubMed PMID: 11108718.
   PubMed Web of Science ®Google Scholar
• Hussain RM, Ciulla TA. Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration. Expert Opin Emerg Drugs. 2017 Sep;22(3):235–246. PubMed PMID: 28756707.
   PubMed Web of Science ®Google Scholar
• Ciulla TA, Bracha P, Pollack J, et al. Real-world outcomes of anti-vascular endothelial growth factor therapy in diabetic macular edema in the United States. Ophthalmol Retina. 2018 Dec;2(12):1179–1187. PubMed PMID: 31047187.
   PubMedGoogle Scholar
• Ciulla TA, Hussain RM, Pollack JS, et al. Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular AMD patients: a “real world” analysis in 49,485 eyes. Ophthalmol Retina. 2019 May 25:pii: S2468-6530(19)30280-5. doi: 10.1016/j.oret.2019.05.017. [ epub ahead of print].
   PubMedGoogle Scholar
• Puri MC, Rossant J, Alitalo K, et al. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. Embo J. 1995 Dec 1;14(23):5884–5891. PubMed PMID: 8846781; PubMed Central PMCID: PMCPMC394706.
   PubMed Web of Science ®Google Scholar
• Asahara T, Chen D, Takahashi T, et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res. 1998 Aug 10;83(3):233–240. PubMed PMID: 9710115.
   PubMed Web of Science ®Google Scholar
• Augustin HG, Koh GY, Thurston G, et al. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol. 2009 Mar;10(3):165–177. PubMed PMID: 19234476.
   PubMed Web of Science ®Google Scholar
• Nambu H, Nambu R, Oshima Y, et al. Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood-retinal barrier. Gene Ther. 2004 May;11(10):865–873. PubMed PMID: 15042118.
   PubMed Web of Science ®Google Scholar
• Hammes HP, Feng Y, Pfister F, et al. Diabetic retinopathy: targeting vasoregression. Diabetes. 2011 Jan;60(1):9–16. PubMed PMID: 21193734; PubMed Central PMCID: PMCPMC3012202.
   PubMed Web of Science ®Google Scholar
• Lee J, Park DY, Park DY, et al. Angiopoietin-1 suppresses choroidal neovascularization and vascular leakage. Invest Ophthalmol Vis Sci. 2014 Apr 7;55(4):2191–2199. PubMed PMID: 24609620.
   PubMed Web of Science ®Google Scholar
• Nambu H, Umeda N, Kachi S, et al. Angiopoietin 1 prevents retinal detachment in an aggressive model of proliferative retinopathy, but has no effect on established neovascularization. J Cell Physiol. 2005 Jul;204(1):227–235. PubMed PMID: 15648096.
   PubMed Web of Science ®Google Scholar
• Ziegler T, Horstkotte J, Schwab C, et al. Angiopoietin 2 mediates microvascular and hemodynamic alterations in sepsis. J Clin Invest. 2013 Jul 1. PubMed PMID: 23863629; PubMed Central PMCID: PMCPMC3726157. DOI:10.1172/JCI66549.
   PubMed Web of Science ®Google Scholar
• Menden H, Welak S, Cossette S, et al. Lipopolysaccharide (LPS)-mediated angiopoietin-2-dependent autocrine angiogenesis is regulated by NADPH oxidase 2 (Nox2) in human pulmonary microvascular endothelial cells. J Biol Chem. 2015 Feb 27;290(9):5449–5461. PubMed PMID: 25568324; PubMed Central PMCID: PMCPMC4342461.
   PubMed Web of Science ®Google Scholar
• Oshima Y, Deering T, Oshima S, et al. Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor. J Cell Physiol. 2004 Jun;199(3):412–417. PubMed PMID: 15095288.
   PubMed Web of Science ®Google Scholar
• Oshima Y, Oshima S, Nambu H, et al. Different effects of angiopoietin-2 in different vascular beds: new vessels are most sensitive. Faseb J. 2005 Jun;19(8):963–965. PubMed PMID: 15802489.
   PubMed Web of Science ®Google Scholar
• Watanabe D, Suzuma K, Suzuma I, et al. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2005 Mar;139(3):476–481. PubMed PMID: 15767056.
   PubMed Web of Science ®Google Scholar
• Loukovaara S, Robciuc A, Holopainen JM, et al. Ang-2 upregulation correlates with increased levels of MMP-9, VEGF, EPO and TGFbeta1 in diabetic eyes undergoing vitrectomy. Acta Ophthalmol. 2013 Sep;91(6):531–539. PubMed PMID: 23106921.
   PubMed Web of Science ®Google Scholar
• Oh H, Takagi H, Suzuma K, et al. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem. 1999 May 28;274(22):15732–15739. PubMed PMID: 10336473.
   PubMed Web of Science ®Google Scholar
• Ohashi H, Takagi H, Koyama S, et al. Alterations in expression of angiopoietins and the Tie-2 receptor in the retina of streptozotocin induced diabetic rats. Mol Vis. 2004 Aug;26(10):608–617. PubMed PMID: 15354084.
   Google Scholar
• Rangasamy S, Srinivasan R, Maestas J, et al. A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2011 Jun 1;52(6):3784–3791. PubMed PMID: 21310918; PubMed Central PMCID: PMCPMC3109054.
   PubMed Web of Science ®Google Scholar
• Park SW, Yun JH, Kim JH, et al. Angiopoietin 2 induces pericyte apoptosis via alpha3beta1 integrin signaling in diabetic retinopathy. Diabetes. 2014 Sep;63(9):3057–3068. PubMed PMID: 24722242.
   PubMed Web of Science ®Google Scholar
• Lee SG, Lee CG, Yun IH, et al. Effect of lipoic acid on expression of angiogenic factors in diabetic rat retina. Clin Exp Ophthalmol. 2012 Jan–Feb;40(1):e47–57. PubMed PMID: 21902786.
   PubMed Web of Science ®Google Scholar
• Sugimachi K, Tanaka S, Taguchi K, et al. Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma. J Clin Pathol. 2003 Nov;56(11):854–860. PubMed PMID: 14600132; PubMed Central PMCID: PMCPMC1770094.
   PubMed Web of Science ®Google Scholar
• Tait CR, Jones PF. Angiopoietins in tumours: the angiogenic switch. J Pathol. 2004 Sep;204(1):1–10. PubMed PMID: 15307132.
   PubMed Web of Science ®Google Scholar
• Orfanos SE, Kotanidou A, Glynos C, et al. Angiopoietin-2 is increased in severe sepsis: correlation with inflammatory mediators. Crit Care Med. 2007 Jan;35(1):199–206. PubMed PMID: 17110873.
   PubMed Web of Science ®Google Scholar
• Fachinger G, Deutsch U, Risau W. Functional interaction of vascular endothelial-protein-tyrosine phosphatase with the angiopoietin receptor Tie-2 [Short report]. Oncogene. 1999 Oct 21;18:5948.
   PubMed Web of Science ®Google Scholar
• Frye M, Dierkes M, Kuppers V, et al. Interfering with VE-PTP stabilizes endothelial junctions in vivo via Tie-2 in the absence of VE-cadherin. J Exp Med. 2015 Dec 14;212(13):2267–2287. PubMed PMID: 26642851; PubMed Central PMCID: PMCPMC4689167.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Peters KG. Targeting Tie2 for treatment of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2016 Dec;16(12):126. 10.1007/s11892-016-0816-5. PubMed PMID: 27778249.
   PubMed Web of Science ®Google Scholar
• Regula JT, Lundh von Leithner P, Foxton R, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016 Nov;8(11):1265–1288. PubMed PMID: 27742718; PubMed Central PMCID: PMCPMC5090659.
   PubMed Web of Science ®Google Scholar
• Brown DM. Phase 1 study of combination therapy with nesvacumab and aflibercept for neovascular AMD and diabetic macular edema. Presented at the American Academy of Ophthalmology annual meeting; Chicago (IL); 2016.
   Google Scholar
• Boyer DS., editor. Aflibercept combination therapies: rinucumab/aflibercept and nesvacumab/aflibercept. Presented at the American Academy of Ophthalmology annual meeting; Chicago (IL); 2016.
   Google Scholar
• Rodriguez M. ASRS 2018: diabetic retinopathy session 1; [cited 2018 Jul 25]. Available from: https://retinaroundup.com/2018/07/25/asrs-2018-diabetic-retinopathy-session-1/
   Google Scholar
• Helzner J. Eylea/Ang2 combo disappoints in phase 2. Retinal Physician. 2017 Nov/Dec.
   Google Scholar
• Chakravarthy U, Bailey C, Brown D, et al. Phase I trial of anti-vascular endothelial growth factor/anti-angiopoietin 2 bispecific antibody RG7716 for neovascular age-related macular degeneration. Ophthalmol Retina. 2017 Nov–Dec;1(6):474–485. PubMed PMID: 31047438.
   PubMedGoogle Scholar
• Helzner J. Faricimab shows potential for 16-week dosing. Retinal Physician. 2018 Sep.
   Google Scholar
• Khanani AM., editor. Simultaneous inhibition of VEGF and Ang-2 with faricimab in neovascular AMD: STAIRWAY phase 2 results. Presented at the American Academy of Ophthalmology annual meeting; Chicago; 2018.
   Google Scholar
• Sahni J, Patel SS, Dugel PU, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial. Ophthalmology. 2019 Mar 21;126:1155–1170.
   PubMed Web of Science ®Google Scholar
• Kirkner RM. What’s next for bispecific antibody faricimab? Retina Specialist. 2018 Nov.
   Google Scholar
• Fauser SBoulevard: phase 2 results of the bispecific VEGF/Ang2 antibody in diabetic macular edema. Presented at the Angiogenesis, Exudation, and Degeneration Meeting; Miami (FL); 2018.
   Google Scholar
• Shen J, Frye M, Lee BL, et al. Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature. J Clin Invest. 2014 Oct;124(10):4564–4576. PubMed PMID: 25180601; PubMed Central PMCID: PMCPMC4191011.
   PubMed Web of Science ®Google Scholar
• ARP-1536. [cited 2019 Jul 7]. Available from: https://aerpio.com/pipeline/arp-1536/
   Google Scholar
• Campochiaro PA, Khanani A, Singer M, et al. Enhanced benefit in diabetic macular edema from AKB-9778 Tie2 activation combined with vascular endothelial growth factor suppression. Ophthalmology. 2016 Aug;123(8):1722–1730. PubMed PMID: 27236272.
   PubMed Web of Science ®Google Scholar
• Hoffman, S. Time-2b clinical trial: AKB-9778 in non-proliferative diabetic retinopathy. Presented at the18th Annual Needham Conference; Oct 4; New York (NY); 2019.
   Google Scholar
• Asclepix therapuetics: pipeline; [cited 2019 Jul 7]. Available from: http://www.asclepix.com/pipeline/
   Google Scholar
• Mirando AC, Shen J, Silva RLE, et al. A collagen IV-derived peptide disrupts alpha5beta1 integrin and potentiates Ang2/Tie2 signaling. JCI Insight. 2019 Feb 21;4(4):pii:122043  PubMed PMID: 30668550; PubMed Central PMCID: PMCPMC6478425.
   PubMed Web of Science ®Google Scholar
• Silva RLE, Kanan Y, Mirando AC, et al. Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage. Sci Transl Med. 2017 Jan 18;9(373):pii:eaai8030. PubMed PMID: 28100839; PubMed Central PMCID: PMCPMC5308917.
   PubMed Web of Science ®Google Scholar
• Perrow W. Asclepix therapeutics: breakthrough next gen therapies for retinal diseases. Presented at the Ophthalmic Innovations Summit; Chicago (IL); 2019.
   Google Scholar
• Al-Khersan H, Hussain RM, Ciulla TA, et al. Innovative therapies for neovascular age-related macular degeneration. Expert Opin Pharmacother. 2019 Jul 12:1–13. PubMed PMID: 31298960. DOI: 10.1080/14656566.2019.1636031
   PubMed Web of Science ®Google Scholar
• Opthea meets primary endpoint in phase 2b study of OPT-302 in wet AMD [Internet]; Published 2019 Jul 8. Available from: https://www.opthea.com/wp-content/uploads/2019/08/OPT.-2019_08_07_ASX_Ph2b-wAMD-Results_Final.pdf
   Google Scholar
• Allegro Ophthalmics. Risuteganib (LUMINATE®): potential paradigm shift in the treatment of oxidative stress-induced DME. Presented at the Ophthalmic Innovations Summit; Chicago (IL); 2018.
   Google Scholar